NASDAQ:KLRA Kailera Therapeutics Q1 2026 Earnings Results & Report $12.20 -0.37 (-2.94%) As of 04:00 PM Eastern Kailera Therapeutics reported Q1 2026 earnings on May 26, 2026. The company reported EPS of -$3,650.00. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2026Report DateMay 26, 2026TimeAfter Market ClosesConference Call4:00 PM ET Kailera Therapeutics EPS ResultsActual EPS-$3,650.00Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AKailera Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Kailera Therapeutics Q1 2026 Earnings FAQ Did Kailera Therapeutics beat earnings estimates for Q1 2026? Kailera Therapeutics (NASDAQ:KLRA) reported earnings of -$3,650.00 per share for Q1 2026. The report was announced on Tuesday, May 26, 2026. Kailera Therapeutics Earnings HeadlinesCanaccord Genuity Group Begins Coverage on Kailera Therapeutics (NASDAQ:KLRA)November 11, 2026 | americanbankingnews.comKailera Therapeutics to Present at ObesityWeek 2026November 10, 2026 | globenewswire.comDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall. The free download walks through strategies for navigating the options market, but the window to claim it is closing soon.November 17 at 1:00 AM | TradeWins (Ad)Kailera Therapeutics: Phase 3 obesity launch set for 2027November 5, 2026 | 247wallst.comKailera Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 5, 2026 | marketscreener.comMKailera Reports Third Quarter 2026 Financial Results and Provides Business UpdatesNovember 4, 2026 | globenewswire.comSee More Kailera Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Kailera Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kailera Therapeutics and other key companies, straight to your email. Email Address About Kailera TherapeuticsKailera Therapeutics (NASDAQ:KLRA) is a clinical-stage biopharmaceutical company developing medicines for obesity and related metabolic diseases. Its research focuses on treatments that act on biological pathways involved in appetite, weight regulation and metabolism. The company’s pipeline includes investigational injectable and oral therapies, including programs designed to target GLP-1 and GIP receptors. These products are in development and are not approved for commercial use. Founded in 2024, Kailera has secured development and commercialization rights outside Greater China to drug candidates discovered by Jiangsu Hengrui Pharmaceuticals. The company is based in Watertown, Massachusetts, and is led by President and Chief Executive Officer Ron Renaud.View Kailera Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its YearThe Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to WatchTyson Foods' Earnings Beat Hides a Warning for Consumer Staples Dividend InvestorsMongoDB's Biggest Advantage May Be GitLab's Biggest WeaknessMicrosoft's Outage Barely Moved Its Stock, But a Bigger Risk May Be BuildingTyson Foods' 10% Surge Puts a Breakout in Sight, But Wall Street Remains CautiousOndas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog? Upcoming Earnings Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026)Ross Stores (11/19/2026)Walmart (11/19/2026)Intuit (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.